Zynerba plans to start a pivotal phase 2/3 trial next year. A phase 2 trial of Zynerba Pharmaceuticals’ Fragile X syndrome drug met its primary endpoint. The beleaguered biotech’s stock doubled on ...
What Is Fragile X Syndrome? Fragile X syndrome, also known as Martin-Bell syndrome, is a genetic condition that affects a child's learning, behavior, appearance, and health. Symptoms can be mild or ...
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X ...
Plans advancing to initiate a clinical trial in individuals with FXS NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results